by Don McLean | Feb 7, 2019 | Blog
Safety Writing, REMS, and Regulatory Requirements: A Conversation with Jeffrey Wiese by Staff writer In this Expert Insights interview, we sit down with Jeffrey Wiese, Senior Safety Writer at MMS – to discuss safety writing in the pharmaceutical industry,...
by Don McLean | Oct 25, 2018 | Blog
Four initiatives to combat the opioid epidemic by Jeffrey Wiese and Julie Legakis This article was drafted based on a presentation given at the 9th Annual Scientific Symposium presented at MMS global headquarters in Canton, Mich. Opioid use in the U.S. is widespread....
by Don McLean | Jun 28, 2018 | Blog
An industry-wide need to improve future REMS assessments by Christine Tervo, MS There are currently more than 70 approved Risk Evaluation and Mitigation Strategies (REMS) in the Food and Drug Administration (FDA) database. These structured programs are designed with...
